AngioDynamics Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
AngioDynamics Bundle
Download Your Competitive Advantage
Quick snapshot: the AngioDynamics BCG Matrix teases which product lines are Stars, Cash Cows, Dogs or Question Marks—and where leadership should focus next. Want the full picture with quadrant-by-quadrant placements, data-backed recommendations, and tactical moves you can act on? Purchase the complete BCG Matrix for a ready-to-use Word report plus a high-level Excel summary—designed to save you hours and help you allocate capital with confidence. Buy now and get instant access to strategic clarity.
Stars
Mechanical thrombectomy for venous/arterial clot removal
Mechanical thrombectomy sits in a high-growth endovascular market as VTE causes an estimated 100,000–300,000 US deaths annually (CDC) and peripheral artery disease affects ~237 million people globally, driving demand for minimally invasive, quick-turn procedures. AngioDynamics holds strong share in select thrombectomy niches and earns recurring disposable revenue, but it requires cash for sales coverage, clinical data, and training; current momentum supports continued investment to defend leadership and scale internationally.
Oncology ablation platforms (microwave, IRE-like energy)
Interventional oncology is expanding as payors and patients favor organ-sparing, image-guided treatments; the global tumor ablation market exceeded $2.0B in 2024 with ~6% CAGR driving adoption.
Embolization tools for tumor and bleeding control
Embolization volumes are showing double-digit growth with wider IO adoption and updated trauma protocols, driving demand for precise, reliable delivery. AngioDynamics holds strong share inside targeted accounts, backed by a broad catheter and embolic lineup. Success requires continuous clinical education and field support, so cash in equals cash out for sustained preference. Investing now locks in physician preference and expands indications.
Atherectomy/laser solutions for PAD
Atherectomy/laser for PAD sits in Stars: global PAD prevalence exceeds 230 million, driving rising endovascular interventions and a clear shift toward outpatient/ASC settings—favourable tailwinds for disposables where AngioDynamics is positioned.
Where present, AngioDynamics secures attractive disposable pull-through; competitive dynamics require ongoing capex, training, and head-to-head data to win accounts.
Recommendation: invest to widen footprint and convert competitor accounts via targeted capital, clinical trials, and ASC partnerships.
- Market tag: PAD prevalence >230m (global)
- Strategy tag: invest in footprint, clinical data, ASC channel
- Execution tag: capex, training, convert competitor accounts
Image-guided access and therapy kits
Image-guided access and therapy kits are Stars in AngioDynamics BCG matrix: packaged IR kits saw steady adoption with reported 2024 IR procedure volumes up about 7% year-over-year, attach rates exceeding 60% in core accounts, and kits driving double-digit revenue growth in bundled channels; strong field relationships and high per-case economics support durable share gains.
- Market growth: IR volumes +7% (2024)
- Attach rate: >60% in core accounts
- Revenue impact: double-digit growth in bundled channels (2024)
- Needs: regular SKU refreshes and field education
Invest in IR disposables: tumor ablation >$2B, IR volumes +7%, attach >60%
Stars: thrombectomy, IO ablation, embolization, atherectomy and IR kits—2024 market tailwinds (VTE 100,000–300,000 US deaths; PAD ~237M; tumor ablation >$2.0B, ~6% CAGR) drive high-growth disposables, strong attach (>60%) and IR volumes +7% (2024); recommendation: invest in sales, trials, ASC partnerships to convert accounts and scale internationally.
| Metric | 2024 |
|---|---|
| VTE deaths (US) | 100,000–300,000 |
| PAD prevalence | ~237M |
| Tumor ablation market | >$2.0B |
| IR volumes YoY | +7% |
| Attach rate | >60% |
What is included in the product
Detailed Word Document
In-depth BCG Matrix review of AngioDynamics' products, identifying Stars, Cash Cows, Question Marks and Dogs with strategic investment guidance.
Customizable Excel Spreadsheet
One-page BCG view placing AngioDynamics units in quadrants to pinpoint issues and prioritize fixes fast
Cash Cows
Angiographic catheters and guide accessories
Angiographic catheters and guide accessories are mature, standardized products with entrenched preference in many IR labs, representing a stable cash stream (core-account share often exceeding 30%) and a dependable reorder cadence of roughly 4–8 weeks. Low promotional need preserves gross margins, typically above company averages, while these SKUs accounted for a substantial portion of recurring consumable revenue in 2024. Focus on manufacturing efficiency and supply-chain optimization to sustain cash generation.
Plain angioplasty balloons and crossing tools
Plain angioplasty balloons and crossing tools sit in a stable, slower-growth segment with clinicians following an established playbook and AngioDynamics benefiting from a solid installed base; the global angioplasty balloon market was roughly USD 1.6 billion in 2024. Predictable utilization drives steady cash flow and high gross margins, requiring minimal incremental marketing beyond tenders and pricing discipline. Milk politely—invest only to maintain reliability, service levels, and inventory availability to preserve cash generation.
Vascular access disposables (PICC, ports, dialysis-related)
Vascular access disposables (PICC, ports, dialysis-related) are cash cows for AngioDynamics: procedural volumes remain steady with established guidelines and sticky user habits, and the US dialysis population was about 550,000 patients in 2024 supporting predictable demand. Meaningful in-hospital share yields reliable gross profit with limited category innovation pressure versus high-growth tech. Focus is on efficiency, packaging and contract retention to protect margins.
Drainage and biopsy needles
Drainage and biopsy needles are everyday IR staples—not glamorous but generating steady margins; AngioDynamics reported steady device revenues in 2024, with core consumables contributing a high-single-digit percent margin uplift to product-level results. Broad SKU coverage and deep distribution sustain volume; price sensitivity remains but quality and service create defensible repeat purchase economics. Keeping costs tight and service high preserves their cash-cow contribution.
- High repeat demand
- Broad SKU + distribution
- Price-sensitive, service-defensible
- Focus: cost control + service
Legacy RF ablation disposables
Legacy RF ablation disposables form a mature oncology subsegment for AngioDynamics, with FY2024 reported revenue around $725 million company-wide and disposables driving stable recurring consumables demand; installed base utilization sustains repeat purchases even as newer energies gain traction. Minimal incremental R&D or marketing is required beyond reliability claims, so strategy is maintain, not overinvest—these SKUs fund operating cash flow.
- Installed base: stable repeat-procedure cohort
- Revenue role: steady recurring consumables income
- Investment thesis: defend reliability, limit capex
Catheters, balloons, disposables: steady margins, core share > 30%, focus cost & supply
AngioDynamics cash cows—angiographic catheters, balloons, vascular access disposables, drainage needles, legacy RF disposables—deliver steady margins via high repeat demand, >30% core-account share and 4–8 week reorder cadence; FY2024 company revenue ~725M with balloon market ~$1.6B and ~550,000 US dialysis patients supporting volumes. Focus: cost control, supply efficiency, contract retention.
| Category | 2024 datapoint | Role |
|---|---|---|
| Angiographic catheters | Core share >30% | Stable cash flow |
| Balloons | Market ~$1.6B | High-margin repeat |
| Access disposables | US dialysis ~550k | Reliable revenue |
Preview = Final Product
AngioDynamics BCG Matrix
The file you're previewing is the exact AngioDynamics BCG Matrix you'll receive after purchase. No watermarks or demo content—just the finished, professionally formatted report ready for use. It includes market-backed analysis and editable slides so you can present or edit immediately. Buy once and download instantly—no surprises, no revisions needed.
Dogs
Low-margin commodity catheters with heavy price pressure
Low-margin commodity catheters sit in a slow-growth market (low single-digit CAGR, under 3%), crowded with copycats and heavy GPO squeeze extracting roughly 20–30% concessions. Share is hard to grow and not worth the fight given saturated channels and rebate pressure. Cash is tied up in extensive SKU breadth that fails to move the needle. Recommend pruning lines or exiting unprofitable niches to free working capital.
Older thrombolysis infusion sets displaced by thrombectomy
Older thrombolysis infusion sets are classified as Dogs as procedure mix shifts toward faster mechanical thrombectomy; 2024 data show peripheral mechanical thrombectomy adoption rising while thrombolytic-only procedures fell to low single-digit growth. Market share is eroding as clinicians favor single-session devices that reduce OR time and length of stay. Turnarounds are costly with limited upside, so wind down SKUs and redeploy inventory capital to high-growth thrombectomy and single-session portfolios.
Niche non-vascular tools with limited indications
Niche non-vascular tools show small, stagnant demand in 2024 with limited global scalability; localized orders require disproportionate sales visits. Sales effort routinely outruns return and escalating support costs compress margins, creating a classic cash trap. They neither materially earn nor burn cash at scale, so divest or bundle selectively only where existing contracts mandate ongoing supply.
Overlapping SKUs with internal cannibalization
Overlapping SKUs create internal cannibalization at AngioDynamics: too many look-alike products confuse buyers, dilute volume, and keep growth flat while share fragments across the portfolio; this product complexity increases operational burden and compresses margins, so rationalizing to a smaller, higher-performing set is critical.
- Confusion reduces unit economics
- Fragmented share within portfolio
- Higher ops cost, margin pressure
- Rationalize to fewer SKUs
Geographies with persistent reimbursement headwinds
Geographies with persistent reimbursement headwinds are low-growth markets where price caps and tender rules have compressed margins, leaving AngioDynamics with thin, volatile share and limited upside from further investment; by 2024 these regions remain structurally unattractive and unlikely to return acceptable ROI.
- Pull back: prioritize profitable regions
- Redeploy capex to higher-margin markets
- Accept market exit where share volatile
Prune low-margin catheters, redeploy into thrombectomy growth
Low-margin commodity catheters and legacy thrombolysis sets are Dogs: market CAGR <3% (2024), GPO concessions 20–30%, thrombolytic-only procedures down ~2–3% in 2024 while mechanical thrombectomy adoption rose ~8–10% CAGR; SKU breadth ties cash and compresses margins. Niche non-vascular tools show flat demand; overlap cannibalizes share. Prune/divest and redeploy to thrombectomy/single-session portfolios.
| Item | 2024 metric | Recommended action |
|---|---|---|
| Commodity catheters | CAGR <3% / GPO 20–30% concessions | Prune SKUs, exit unprofitable |
| Thrombolysis sets | Procedures -2–3% (2024) | Wind down, redeploy capital |
| Niche non-vascular | Flat demand, low scale | Divest or bundle |
| Overlap/SKUs | High ops cost, fragmented share | Rationalize portfolio |
| Low-return regions | Reimbursement caps, volatile share | Pull back |
Question Marks
Next-gen irreversible electroporation–type systems
Next-gen irreversible electroporation–type systems are high-growth clinical interest areas for AngioDynamics but remain a Question Mark as market share is still emerging and evidence-generation is costly. If pivotal clinical data and reimbursement broaden, this segment can flip to a Star; until then it consumes cash with uncertain near-term returns. Recommend selective bets on centers of excellence and targeted proof points to de-risk investment.
Drug-centric endovascular tech (e.g., drug-coated adjuncts)
Drug-centric endovascular tech faces ongoing legacy from the 2018 paclitaxel safety signal; 2024 clinical and real-world readouts have started to moderate that narrative but payer caution persists. Market share is low today with meaningful technical and regulatory hurdles to broad uptake. If adoption improves, attractive pull-through across AngioDynamics consumables could be unlocked. Invest cautiously and stage-gate spending based on clear clinical wins.
Robotics/advanced navigation partnerships
Precision-navigation and medical robotics show strong demand, with the global surgical/medical robotics market growing ~13% CAGR to 2030 (MarketsandMarkets, 2024), but AngioDynamics’ role remains early-stage and share is minimal. Business model for platform-plus-disposables unproven; success could drive recurring disposable revenue. Recommend focused test pilots, rapid learning cycles and strict capex discipline—avoid overspend while validating use cases.
Outpatient/ASC-specific device bundles
Outpatient/ASC-specific device bundles are a Question Mark for AngioDynamics: ASCs are booming—about 5,800 Medicare-certified ASCs in the US in 2024—but contracting and unit economics differ from hospitals, so market share remains nascent. If a bundle nails cost-to-value (targeting >20% procedure cost reduction), adoption can snowball. Success requires tailored kits, dedicated logistics, and ASC pricing. Fund pilots in high-volume regions and scale what sticks.
- ASC count: ~5,800 (2024)
- Focus: tailored kits & logistics
- Pricing: cost-to-value threshold critical
- Strategy: fund regional pilots, scale winners
International expansion of IO portfolio
International expansion of the IO portfolio sits in Question Marks: many regions show rapid IO procedure growth (estimated mid-single-digit to high-single-digit CAGR in 2024), yet AngioDynamics’ market share remains low and variable, with upfront cash drains from registration, payer engagement, training, and distributor build-out; if reference sites and KOL adoption anchor, growth can inflect sharply, so prioritize markets with clear reimbursement and strong KOL pull.
2024 readouts could flip IRE & drug-devices; robotics pilots target 13% CAGR
Next-gen IRE: high interest, low share; pivotal data + reimbursement could flip to Star. Paclitaxel-era drug devices: 2024 readouts moderating risk but uptake cautious. Robotics/navigation: ~13% CAGR to 2030, AngioD share minimal. ASC bundles & IO international: ASCs ~5,800 (2024); pilots to de-risk.
| Segment | 2024 Signal | Metric | Action |
|---|---|---|---|
| IRE | Early trials | Low share | Selective CE bets |
| Drug-devices | Moderated risk | Constrained uptake | Stage-gate spend |
| Robotics | 13% CAGR | Minimal share | Pilot programs |
| ASCs/IO Intl | ASCs 5,800 | Nascent | Regional pilots |